Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 126,800 shares, an increase of 7.1% from the November 30th total of 118,400 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 37,000 shares, the short-interest ratio is currently 3.4 days.

Aytu BioPharma Stock Performance

NASDAQ:AYTU opened at $1.70 on Thursday. The company’s 50-day moving average price is $1.66 and its 200-day moving average price is $2.25. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35. The company has a market cap of $10.45 million, a P/E ratio of -1.38 and a beta of -1.40. Aytu BioPharma has a twelve month low of $1.30 and a twelve month high of $3.45.

Hedge Funds Weigh In On Aytu BioPharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC lifted its stake in shares of Aytu BioPharma by 6.0% in the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock worth $1,177,000 after buying an additional 28,489 shares in the last quarter. Armistice Capital LLC purchased a new position in shares of Aytu BioPharma in the second quarter worth about $736,000. Finally, Dimensional Fund Advisors LP increased its position in Aytu BioPharma by 54.5% during the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after purchasing an additional 8,311 shares during the last quarter. 33.49% of the stock is owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.